Jazz Pharmaceuticals (JAZZ) FY2022 results: revenue $3.7 billion, up 18.3% on the year
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $3.7 billion for fiscal 2022, the year ended 31 December 2022, up 18.3% on the year before. Net income was -$224 million, and diluted earnings per share $-3.58. The figures are the company's own, from the 10-K it filed with the SEC on 1 March 2023.
Revenue
$3.7 billion
+18.3% on the year
FY2015FY2022
Operating margin
-1.8%
5.5% a year earlier
FY2015FY2022
Net income
-$224 million
FY2015FY2022
Diluted EPS
-$3.58
FY2015FY2022
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2022
FY2021
FY2020
On the year
Last 8 years
Operating cash flow
1,272
779
900
+63.4%
Capital expenditure
29.0
27.6
15.0
+5.1%
Free cash flow
1,243
751
885
+65.5%
Free cash flow margin
34.0%
24.3%
37.4%
Cash from investing
-446
-5,212
-1,008
Cash from financing
-529
3,971
528
Depreciation and amortisation
30.3
26.7
18.7
+13.5%
Share-based compensation
222
189
121
+17.5%
Buybacks
0.1
0.0
147
Diluted shares, weighted
63m
60m
57m
+4.8%
Shares outstanding at period end
63m
62m
56m
+2.6%
Balance sheet
$ million
FY2022
FY2021
FY2020
On the year
Last 8 years
Shareholders' equity
3,086
3,965
3,660
-22.2%
Debt
5,724
6,050
2,095
-5.4%
Operating lease liabilities
71.8
87.2
140
-17.6%
Finance lease liabilities
5.2
6.3
0.0
-16.9%
Other liabilities
1,948
2,190
641
-11.0%
Total liabilities and equity
10,835
12,299
6,536
-11.9%
Fixed assets
n/a
n/a
128
Goodwill
1,693
1,828
958
-7.4%
Intangible assets
5,794
7,152
2,195
-19.0%
Securities held for sale or to maturity
881
591
2,133
+49.0%
Cash and equivalents
881
591
1,058
+49.0%
Receivables
651
563
396
+15.6%
Inventory
714
1,073
95.4
-33.4%
Other assets
220
500
n/a
-56.0%
Total assets
10,835
12,299
6,536
-11.9%
10-K for the year ended 31 December 2022, filed 1 March 2023: the filing.